世界の分子品質管理市場は、売上ベースで2023年に2億ドル相当と推定され、2023年から2028年までに6.6%のCAGRで成長し、2028年までに3億ドルに達する見込みです。このレポートは業界動向の分析で構成され、業界動向、価格分析、特許分析、カンファレンスとウェビナーの資料、主要な利害関係者、市場の購買行動が含まれています。
								
						目次
						
	TABLE OF CONTENTS
	1 INTRODUCTION (Page No. - 24)
	
	1.1 STUDY OBJECTIVES
	1.2 MARKET DEFINITION
	1.2.1 INCLUSIONS AND EXCLUSIONS
	1.3 MARKET SCOPE
	1.3.1 MARKETS COVERED
	1.3.2 YEARS CONSIDERED
	1.4 CURRENCY CONSIDERED
	TABLE 1 STANDARD CURRENCY CONVERSION RATES
	1.5 STUDY LIMITATIONS
	1.6 STAKEHOLDERS
	1.7 SUMMARY OF CHANGES
	1.8 RECESSION IMPACT
	2 RESEARCH METHODOLOGY (Page No. - 29)
	
	2.1 RESEARCH DATA
	FIGURE 1 RESEARCH DESIGN
	2.2 RESEARCH DESIGN
	2.2.1 SECONDARY RESEARCH
	2.2.1.1 Key data from secondary sources
	2.2.2 PRIMARY RESEARCH
	FIGURE 2 PRIMARY SOURCES
	2.2.2.1 Key data from primary sources
	FIGURE 3 INSIGHTS FROM INDUSTRY EXPERTS
	2.2.2.2 Breakdown of primaries
	FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
	2.3 MARKET SIZE ESTIMATION
	FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
	FIGURE 6 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS
	FIGURE 7 MARKET SIZE ESTIMATION: PARENT MARKET
	FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
	FIGURE 9 MOLECULAR QUALITY CONTROLS INDUSTRY: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
	2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
	FIGURE 10 DATA TRIANGULATION METHODOLOGY
	2.5 MARKET SHARE ANALYSIS
	2.6 STUDY ASSUMPTIONS
	2.7 RISK ASSESSMENT
	TABLE 2 MARKET: RISK ASSESSMENT ANALYSIS
	2.8 MARKET LIMITATIONS
	2.8.1 METHODOLOGY-RELATED LIMITATIONS
	2.8.2 SCOPE-RELATED LIMITATIONS
	2.9 RECESSION IMPACT ANALYSIS
	3 EXECUTIVE SUMMARY (Page No. - 45)
	
	FIGURE 11 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
	FIGURE 12 MOLECULAR QUALITY CONTROLS INDUSTRY, BY ANALYTE TYPE, 2023 VS. 2028 (USD MILLION)
	FIGURE 13 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
	FIGURE 14 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
	FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MARKET
	4 PREMIUM INSIGHTS (Page No. - 49)
	
	4.1 MOLECULAR QUALITY CONTROLS MARKET OVERVIEW
	FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET
	4.2 MOLECULAR QUALITY CONTROLS INDUSTRY, BY PRODUCT
	FIGURE 17 INSTRUMENT-SPECIFIC CONTROLS SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
	4.3 ASIA PACIFIC: MARKET, BY APPLICATION AND COUNTRY
	FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT IN JAPAN ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
	4.4 MARKET: GEOGRAPHICAL MIX
	FIGURE 19 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
	4.5 MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS
	FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
	5 MARKET OVERVIEW (Page No. - 54)
	
	5.1 INTRODUCTION
	FIGURE 21 MOLECULAR QUALITY CONTROLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
	5.1.1 DRIVERS
	5.1.1.1 Rising number of accredited clinical laboratories
	FIGURE 22 NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023)
	5.1.1.2 Growing adoption of third-party quality controls
	TABLE 3 THIRD-PARTY INDEPENDENT QUALITY CONTROLS OFFERED BY KEY COMPANIES
	5.1.1.3 Increasing investments in genomics
	TABLE 4 GOVERNMENT FUNDING INITIATIVES FOR GENOMICS RESEARCH (2019−2022)
	5.1.1.4 Growing preference for personalized medicine
	TABLE 5 US: NUMBER OF PERSONALIZED MEDICINES AVAILABLE (2008-2020)
	FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES (2015-2022)
	FIGURE 24 COST OF SEQUENCING PROCEDURES (2016−2021)
	5.1.1.5 Increasing prevalence of infectious diseases and cancer
	FIGURE 25 GLOBAL CANCER INCIDENCE, 2018-2040 (MILLION)
	5.1.1.6 Rising demand for external quality assessment support
	5.1.2 RESTRAINTS
	5.1.2.1 Budgetary constraints in clinical laboratories
	5.1.2.2 Unfavorable reimbursements for molecular tests
	5.1.3 OPPORTUNITIES
	5.1.3.1 Rising demand for multi-analyte controls
	5.1.3.2 Growth opportunities in emerging markets
	5.1.4 CHALLENGES
	5.1.4.1 Stringent regulatory requirements for IVD products
	5.2 INDUSTRY TRENDS
	5.2.1 LYOPHILIZED/FREEZE-DRIED CONTROLS
	TABLE 6 LYOPHILIZED OR FREEZE-DRIED QUALITY CONTROLS OFFERED BY KEY COMPANIES
	5.3 PRICING ANALYSIS
	TABLE 7 PRICE RANGE FOR MOLECULAR QUALITY CONTROLS, BY TYPE (2022)
	5.4 VALUE CHAIN ANALYSIS
	FIGURE 26 VALUE CHAIN ANALYSIS
	5.5 SUPPLY CHAIN ANALYSIS
	FIGURE 27 SUPPLY CHAIN ANALYSIS
	5.6 ECOSYSTEM ANALYSIS
	FIGURE 28 MARKET: ECOSYSTEM MARKET MAP
	5.7 PORTER’S FIVE FORCES ANALYSIS
	TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
	5.7.1 THREAT OF NEW ENTRANTS
	5.7.2 THREAT OF SUBSTITUTES
	5.7.3 BARGAINING POWER OF BUYERS
	5.7.4 BARGAINING POWER OF SUPPLIERS
	5.7.5 INTENSITY OF COMPETITIVE RIVALRY
	5.8 TRADE ANALYSIS
	5.8.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
	5.8.1.1 Import data for diagnostic & laboratory reagents, by country, 2018-2021 (USD million)
	5.8.1.2 Export data for diagnostic & laboratory reagents, by country, 2018-2021 (USD million)
	5.9 TARIFF AND REGULATORY ANALYSIS
	5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	5.9.2 REGULATORY ANALYSIS
	5.9.2.1 North America
	5.9.2.1.1 US
	TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION
	TABLE 11 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL
	TABLE 12 US: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION
	5.9.2.1.2 Canada
	TABLE 13 CANADA: CLASSIFICATION OF IVD PRODUCTS
	TABLE 14 CANADA: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION
	5.9.2.2 Europe
	TABLE 15 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES
	5.9.2.3 Asia Pacific
	5.9.2.3.1 Japan
	5.9.2.3.2 China
	5.9.2.3.3 India
	5.10 PATENT ANALYSIS
	5.10.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
	FIGURE 29 MARKET: TOP PATENT OWNERS AND APPLICANTS (JANUARY 2011-JUNE 2023)
	FIGURE 30 MARKET: TOP APPLICANT JURISDICTIONS (JANUARY 2011-JUNE 2023)
	5.10.2 PATENT PUBLICATION TRENDS
	FIGURE 31 MARKET: PATENT ANALYSIS (JANUARY 2011-FEBRUARY 2023)
	TABLE 16 MARKET: LIST OF PATENTS/PATENT APPLICATIONS (2020-2023)
	5.11 KEY CONFERENCES AND EVENTS
	TABLE 17 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023-2024
	5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
	5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
	FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS
	TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS (%)
	5.12.2 BUYING CRITERIA
	FIGURE 33 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS
	TABLE 19 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS
	5.13 TRENDS AND DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES
	FIGURE 34 MARKET: REVENUE SHIFT
	6 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT (Page No. - 84)
	
	6.1 INTRODUCTION
	TABLE 20 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS
	TABLE 21 MOLECULAR QUALITY CONTROLS INDUSTRY, BY PRODUCT, 2021-2028 (USD MILLION)
	6.2 INDEPENDENT CONTROLS
	6.2.1 MINIMIZED LOT CROSSOVERS FOR LABORATORIES AND LOW OPERATION COSTS TO DRIVE MARKET
	TABLE 22 INDEPENDENT MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS
	TABLE 23 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	6.3 INSTRUMENT-SPECIFIC CONTROLS
	TABLE 24 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS
	TABLE 25 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 26 MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	6.3.1 POLYMERASE CHAIN REACTION
	6.3.1.1 Rising applications in proteomics and genomics to propel market
	TABLE 27 MARKET FOR PCR, BY COUNTRY, 2021-2028 (USD MILLION)
	6.3.2 DNA SEQUENCING AND NGS
	6.3.2.1 Increasing advancements in sequencing technologies to drive market
	TABLE 28 MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2028 (USD MILLION)
	6.3.3 OTHER TECHNOLOGIES
	TABLE 29 MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)
	7 MOLECULAR QUALITY CONTROL MARKET, BY ANALYTE TYPE (Page No. - 94)
	
	7.1 INTRODUCTION
	TABLE 30 MOLECULAR QUALITY CONTROLS INDUSTRY, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	7.2 SINGLE-ANALYTE CONTROLS
	7.2.1 RISING ADOPTION OF SINGLEPLEX ASSAYS IN HOSPITALS TO SUPPORT MARKET GROWTH
	TABLE 31 SINGLE-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS
	TABLE 32 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	7.3 MULTI-ANALYTE CONTROLS
	7.3.1 GROWING PREFERENCE FOR COST-EFFECTIVE CONTROLS TO DRIVE MARKET
	TABLE 33 MULTI-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS
	TABLE 34 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	8 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION (Page No. - 99)
	
	8.1 INTRODUCTION
	TABLE 35 MOLECULAR QUALITY CONTROLS INDUSTRY, BY APPLICATION, 2021-2028 (USD MILLION)
	8.2 INFECTIOUS DISEASE DIAGNOSTICS
	8.2.1 RISING INCIDENCE OF INFLUENZA, TB, AND HIV TO DRIVE MARKET
	TABLE 36 NUMBER OF COVID-19 CASES, BY COUNTRY (FEBRUARY 2023)
	TABLE 37 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
	8.3 ONCOLOGY TESTING
	8.3.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO PROPEL MARKET
	TABLE 38 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
	TABLE 39 MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2021-2028 (USD MILLION)
	8.4 GENETIC TESTING
	8.4.1 ABILITY TO DIAGNOSE RARE DISEASES TO SUPPORT MARKET GROWTH
	TABLE 40 MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2028 (USD MILLION)
	8.5 OTHER APPLICATIONS
	TABLE 41 MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
	9 MOLECULAR QUALITY CONTROLS MARKET, BY END USER (Page No. - 108)
	
	9.1 INTRODUCTION
	TABLE 42 MOLECULAR QUALITY CONTROLS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
	9.2 DIAGNOSTIC LABORATORIES
	9.2.1 INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES TO DRIVE MARKET
	TABLE 43 MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION)
	9.3 HOSPITALS
	9.3.1 ABILITY TO CONDUCT LARGE VOLUME OF DIAGNOSTIC PROCEDURES TO PROPEL MARKET
	TABLE 44 MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
	9.4 IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS
	9.4.1 ADVANCEMENTS IN MOLECULAR TECHNOLOGIES TO SUPPORT MARKET GROWTH
	TABLE 45 MARKET FOR IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
	9.5 ACADEMIC & RESEARCH INSTITUTES
	9.5.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS TO DRIVE MARKET
	TABLE 46 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
	9.6 OTHER END USERS
	TABLE 47 MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
	10 MOLECULAR QUALITY CONTROLS MARKET, BY REGION (Page No. - 117)
	
	10.1 INTRODUCTION
	TABLE 48 MOLECULAR QUALITY CONTROLS INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
	10.2 NORTH AMERICA
	FIGURE 35 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT
	TABLE 49 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 50 NORTH AMERICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 51 NORTH AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 52 NORTH AMERICA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 53 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 54 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.2.1 US
	10.2.1.1 Growing number of accredited clinical laboratories to drive market
	FIGURE 36 US: NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023)
	TABLE 55 US: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 56 US: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 57 US: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 58 US: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 59 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.2.2 CANADA
	10.2.2.1 Rising funding investments for genomic research to propel market
	TABLE 60 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 61 CANADA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 62 CANADA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 63 CANADA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 64 CANADA: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.2.3 NORTH AMERICA: RECESSION IMPACT
	10.3 EUROPE
	TABLE 65 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 66 EUROPE: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 67 EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 68 EUROPE: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 69 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 70 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.3.1 GERMANY
	10.3.1.1 Rising volume of diagnostic tests in clinical settings to drive market
	TABLE 71 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 72 GERMANY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 73 GERMANY: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 74 GERMANY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 75 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.3.2 UK
	10.3.2.1 Growth in life sciences industry to propel market
	TABLE 76 UK: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 77 UK: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 78 UK: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 79 UK: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 80 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.3.3 FRANCE
	10.3.3.1 Rising prevalence of cancer and endocrine disorders to support market growth
	TABLE 81 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 82 FRANCE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 83 FRANCE: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 84 FRANCE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 85 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.3.4 ITALY
	10.3.4.1 Rising incidence of age-associated chronic ailments to support market growth
	TABLE 86 ITALY: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 87 ITALY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 88 ITALY: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 89 ITALY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 90 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.3.5 SPAIN
	10.3.5.1 Increasing demand for prenatal and genetic testing to support market growth
	TABLE 91 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 92 SPAIN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 93 SPAIN: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 94 SPAIN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 95 SPAIN: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.3.6 RUSSIA
	10.3.6.1 Growing acceptance of molecular diagnostics-based personalized medicine to propel market
	TABLE 96 RUSSIA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 97 RUSSIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 98 RUSSIA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 99 RUSSIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 100 RUSSIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.3.7 REST OF EUROPE
	TABLE 101 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 102 REST OF EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 103 REST OF EUROPE: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 104 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 105 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.3.8 EUROPE: RECESSION IMPACT
	10.4 ASIA PACIFIC
	FIGURE 37 ASIA PACIFIC: MARKET SNAPSHOT
	TABLE 106 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 107 ASIA PACIFIC: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 108 ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 109 ASIA PACIFIC: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 110 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 111 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.4.1 JAPAN
	10.4.1.1 Established healthcare system and rising demand for high-quality IVD tests to drive market
	TABLE 112 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 113 JAPAN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 114 JAPAN: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 115 JAPAN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 116 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.4.2 CHINA
	10.4.2.1 Rising R&D investments for advanced molecular tests to drive market
	TABLE 117 CHINA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 118 CHINA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 119 CHINA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 120 CHINA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 121 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.4.3 INDIA
	10.4.3.1 Rising need to secure NABL accreditations to support market growth
	FIGURE 38 INDIA: INCREASING NUMBER OF LABORATORIES WITH NABL ACCREDITATIONS (2012-2020)
	TABLE 122 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 123 INDIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 124 INDIA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 125 INDIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 126 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.4.4 AUSTRALIA
	10.4.4.1 High prevalence of infectious diseases to fuel market
	TABLE 127 AUSTRALIA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 128 AUSTRALIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 129 AUSTRALIA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 130 AUSTRALIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 131 AUSTRALIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.4.5 REST OF ASIA PACIFIC
	TABLE 132 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 133 REST OF ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 134 REST OF ASIA PACIFIC: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 135 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 136 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.4.6 ASIA PACIFIC: RECESSION IMPACT
	10.5 LATIN AMERICA
	TABLE 137 LATIN AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 138 LATIN AMERICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 139 LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 140 LATIN AMERICA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 141 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 142 LATIN AMERICA: MARKET, BY END USER, ‘ 2021-2028 (USD MILLION)
	10.5.1 BRAZIL
	10.5.1.1 Improving healthcare infrastructure to support market growth
	TABLE 143 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 144 BRAZIL: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 145 BRAZIL: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 146 BRAZIL: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 147 BRAZIL: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.5.2 MEXICO
	10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth
	TABLE 148 MEXICO: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 149 MEXICO: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 150 MEXICO: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 151 MEXICO: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 152 MEXICO: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.5.3 REST OF LATIN AMERICA
	TABLE 153 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 154 REST OF LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 155 REST OF LATIN AMERICA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 156 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 157 REST OF LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
	10.5.4 LATIN AMERICA: RECESSION IMPACT
	10.6 MIDDLE EAST & AFRICA
	10.6.1 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
	10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
	TABLE 158 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
	TABLE 159 MIDDLE EAST & AFRICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
	TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY ANALYTE TYPE, 2021-2028 (USD MILLION)
	TABLE 161 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
	TABLE 162 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
	11 COMPETITIVE LANDSCAPE (Page No. - 172)
	
	11.1 OVERVIEW
	11.2 STRATEGIES ADOPTED BY KEY PLAYERS
	11.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
	FIGURE 39 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS
	11.4 MARKET SHARE ANALYSIS
	FIGURE 40 MARKET SHARE ANALYSIS, BY KEY PLAYER (2022)
	TABLE 163 MARKET: INTENSITY OF COMPETITIVE RIVALRY
	11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
	11.5.1 STARS
	11.5.2 EMERGING LEADERS
	11.5.3 PERVASIVE PLAYERS
	11.5.4 PARTICIPANTS
	FIGURE 41 MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
	11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
	11.6.1 PROGRESSIVE COMPANIES
	11.6.2 STARTING BLOCKS
	11.6.3 RESPONSIVE COMPANIES
	11.6.4 DYNAMIC COMPANIES
	FIGURE 42 MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
	11.7 COMPANY FOOTPRINT ANALYSIS
	TABLE 164 MARKET: COMPANY FOOTPRINT ANALYSIS
	TABLE 165 MARKET: ANALYTE TYPE FOOTPRINT ANALYSIS
	TABLE 166 MARKET: APPLICATION FOOTPRINT ANALYSIS
	TABLE 167 MARKET: REGIONAL FOOTPRINT ANALYSIS
	TABLE 168 MARKET: END USER FOOTPRINT ANALYSIS
	11.8 COMPETITIVE SITUATION AND TRENDS
	11.8.1 PRODUCT LAUNCHES & APPROVALS
	TABLE 169 PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-JUNE 2023)
	11.8.2 DEALS
	TABLE 170 DEALS (JANUARY 2020-JUNE 2023)
	11.8.3 OTHER DEVELOPMENTS
	TABLE 171 OTHER DEVELOPMENTS (JANUARY 2020-JUNE 2023)
	12 COMPANY PROFILES (Page No. - 189)
	
	12.1 KEY PLAYERS
	(Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View)*
	12.1.1 LGC LIMITED
	TABLE 172 LGC LIMITED: BUSINESS OVERVIEW
	FIGURE 43 LCG LIMITED: COMPANY SNAPSHOT (2022)
	12.1.2 THERMO FISHER SCIENTIFIC, INC.
	TABLE 173 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
	FIGURE 44 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
	12.1.3 BIO-RAD LABORATORIES, INC.
	TABLE 174 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
	FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
	12.1.4 MICROBIOLOGICS, INC.
	TABLE 175 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW
	12.1.5 ABBOTT LABORATORIES
	TABLE 176 ABBOTT LABORATORIES: BUSINESS OVERVIEW
	FIGURE 46 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
	12.1.6 F. HOFFMANN-LA ROCHE LTD.
	TABLE 177 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
	FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
	12.1.7 ZEPTOMETRIX, LLC
	TABLE 178 ZEPTOMETRIX, LLC: BUSINESS OVERVIEW
	12.1.8 QUIDELORTHO CORPORATION
	TABLE 179 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
	FIGURE 48 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
	12.1.9 QNOSTICS
	TABLE 180 QNOSTICS: BUSINESS OVERVIEW
	12.1.10 MAINE MOLECULAR QUALITY CONTROLS, INC.
	TABLE 181 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW
	12.1.11 RANDOX LABORATORIES LTD.
	TABLE 182 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
	12.1.12 DANAHER CORPORATION
	TABLE 183 DANAHER CORPORATION: BUSINESS OVERVIEW
	FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
	12.1.13 BIO-TECHNE CORPORATION
	TABLE 184 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
	FIGURE 50 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022)
	12.1.14 FORTRESS DIAGNOSTICS
	TABLE 185 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW
	12.1.15 MICROBIX BIOSYSTEMS
	TABLE 186 MICROBIX BIOSYSTEMS: BUSINESS OVERVIEW
	FIGURE 51 MICROBIX BIOSYSTEMS: COMPANY SNAPSHOT (2022)
	12.1.16 GRIFOLS, S.A.
	TABLE 187 GRIFOLS, S.A.: BUSINESS OVERVIEW
	FIGURE 52 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022)
	12.1.17 ANCHOR MOLECULAR
	TABLE 188 ANCHOR MOLECULAR: BUSINESS OVERVIEW
	12.1.18 SPEEDX PTY. LTD.
	TABLE 189 SPEEDX PTY. LTD.: BUSINESS OVERVIEW
	12.1.19 SEEGENE INC.
	TABLE 190 SEEGENE INC.: BUSINESS OVERVIEW
	FIGURE 53 SEEGENE INC: COMPANY SNAPSHOT (2022)
	12.1.20 HELENA LABORATORIES CORPORATION
	TABLE 191 HELENA LABORATORIES CORPORATION: BUSINESS OVERVIEW
	12.2 OTHER PLAYERS
	12.2.1 SERO AS
	TABLE 192 SERO AS: BUSINESS OVERVIEW
	12.2.2 VIRCELL, S.L.
	TABLE 193 VIRCELL, S.L.: BUSINESS OVERVIEW
	12.2.3 STRECK LLC
	TABLE 194 STRECK LLC.: BUSINESS OVERVIEW
	12.2.4 SUN DIAGNOSTICS, LLC
	TABLE 195 SUN DIAGNOSTICS, LLC: BUSINESS OVERVIEW
	12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
	TABLE 196 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW
	*Details on Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
	13 APPENDIX (Page No. - 273)
	
	13.1 DISCUSSION GUIDE
	13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
	13.3 CUSTOMIZATION OPTIONS
	13.4 RELATED REPORTS
	13.5 AUTHOR DETAILS